Sun Pharmaceuticals Industries Ltd

Market Cap
₹ 437653.00 Cr.
Current Price
₹ 1823.00 Cr.
High / Low
₹ 1960.00 Cr. /1209.00 Cr.
Stock P/E
39.00
Book Value
₹ 288.00 Cr.
Dividend Yield
₹ 0.74
ROCE
₹ 44.5 Cr.
ROE
-1.71 %
Face Value
₹ 1

About

Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market.[1] It is the largest pharmaceutical company in India.[2].

Key Points

Pros
    Company has reduced debt. Company is almost debt free. Company has delivered good profit growth of 23.4% CAGR over last 5 years Company has been maintaining a healthy dividend payout of 46.6%
Cons
    The company has delivered a poor sales growth of 10.8% over past five years. Tax rate seems low

Peer comparison

S.No Name CMP Rs. P/E Mar Cap Rs.Cr. Div Yld % NP Qtr Rs.Cr. Qtr Profit Var % Sales Qtr Rs.Cr. Qtr Sales Var % ROCE %
1 UltraTech Cem. 11112.10 38.57 96156.02 2.15 577.70 38.39 1673.90 15.88 39.54
2 Ambuja Cements 11112.10 38.57 96156.02 2.15 577.70 38.39 1673.90 15.88 39.54
3 Shree Cement 11112.10 38.57 96156.02 2.15 577.70 38.39 1673.90 15.88 39.54
4 ACC 11112.10 38.57 96156.02 2.15 577.70 38.39 1673.90 15.88 39.54
5 J K Cements 11112.10 38.57 96156.02 2.15 577.70 38.39 1673.90 15.88 39.54
6 Nuvoco Vistas 11112.10 38.57 96156.02 2.15 577.70 38.39 1673.90 15.88 39.54
7 Prism Johnson 11112.10 38.57 96156.02 2.15 577.70 38.39 1673.90 15.88 39.54

Quarterly Results

Product Segments
Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Salse 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155 4,614
YOY Sales Growth % 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155 4,614
YOY Sales Growth % 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155 4,614
YOY Sales Growth % 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155 4,614
YOY Sales Growth % 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155 4,614
YOY Sales Growth % 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155 4,614
YOY Sales Growth % 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155 4,614

Profit & Loss

Related Party Product Segments
Dec 2012 Dec 2013 Dec 2014 Dec 2015 Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 TTM
Salse 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155 4,614 4,614
YOY Sales Growth % 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155 4,614 4,614
YOY Sales Growth % 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155 4,614 4,614
YOY Sales Growth % 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155 4,614 4,614
YOY Sales Growth % 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155 4,614 4,614
YOY Sales Growth % 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155 4,614 4,614
YOY Sales Growth % 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155 4,614 4,614

Balance Sheet

Corporate actions
Dec 2012 Dec 2013 Dec 2014 Dec 2015 Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 TTM
Equity Capital 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155 4,614 4,614
Reserves 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155 4,614 4,614
Borrowings 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155 4,614 4,614
Other Liabilities 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155 4,614 4,614
Total Liabilities 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155 4,614 4,614
Fixed Assets 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155 4,614 4,614
Total Assets 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155 4,614 4,614

Cash Flows

 
Dec 2012 Dec 2013 Dec 2014 Dec 2015 Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2023 Dec 2024
Cash from Operating Activity 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155
Cash from Investing Activity 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155
Cash from Financing Activity 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155

Ratios

 
Dec 2012 Dec 2013 Dec 2014 Dec 2015 Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2023 Dec 2024
Debtor Days 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155
Inventory Days 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155
Days Payable 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155
Cash Conversion Cycle 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155
Working Capital Days 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155
ROCE % 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155

Shareholding Pattern

Trades
  • Numbers in percentages
Dec 2012 Dec 2013 Dec 2014 Dec 2015 Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2023 Dec 2024
Debtor Days 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155
Inventory Days 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155
Days Payable 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155
Cash Conversion Cycle 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155
Working Capital Days 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155
ROCE % 3,749 4,226 4,427 4,468 3,987 4,537 4,791 5,201 4,435 4,914 5,409 5,155